Progress in pathophysiological understanding and treatment of thrombocytopenia

Immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP), and vaccine-induced immune thrombotic thrombocytopenia (VITT) all have “thrombocytopenia” in their name, and all but congenital TTP are caused by immune mechanisms, but these conditions are quite different in their clinical fe...

Descripción completa

Detalles Bibliográficos
Autor principal: Kashiwagi, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Progress in Hematology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851102/
https://www.ncbi.nlm.nih.gov/pubmed/36656456
http://dx.doi.org/10.1007/s12185-023-03542-w
_version_ 1784872337549557760
author Kashiwagi, Hirokazu
author_facet Kashiwagi, Hirokazu
author_sort Kashiwagi, Hirokazu
collection PubMed
description Immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP), and vaccine-induced immune thrombotic thrombocytopenia (VITT) all have “thrombocytopenia” in their name, and all but congenital TTP are caused by immune mechanisms, but these conditions are quite different in their clinical features and pathophysiology. This review series covers recent progress in pathophysiology and treatment of these diseases, as well as a recent epoch-making clinical trial of induced pluripotent stem cells (iPSC)-derived platelets for patients with thrombocytopenia.
format Online
Article
Text
id pubmed-9851102
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-98511022023-01-20 Progress in pathophysiological understanding and treatment of thrombocytopenia Kashiwagi, Hirokazu Int J Hematol Progress in Hematology Immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP), and vaccine-induced immune thrombotic thrombocytopenia (VITT) all have “thrombocytopenia” in their name, and all but congenital TTP are caused by immune mechanisms, but these conditions are quite different in their clinical features and pathophysiology. This review series covers recent progress in pathophysiology and treatment of these diseases, as well as a recent epoch-making clinical trial of induced pluripotent stem cells (iPSC)-derived platelets for patients with thrombocytopenia. Springer Nature Singapore 2023-01-19 2023 /pmc/articles/PMC9851102/ /pubmed/36656456 http://dx.doi.org/10.1007/s12185-023-03542-w Text en © Japanese Society of Hematology 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Progress in Hematology
Kashiwagi, Hirokazu
Progress in pathophysiological understanding and treatment of thrombocytopenia
title Progress in pathophysiological understanding and treatment of thrombocytopenia
title_full Progress in pathophysiological understanding and treatment of thrombocytopenia
title_fullStr Progress in pathophysiological understanding and treatment of thrombocytopenia
title_full_unstemmed Progress in pathophysiological understanding and treatment of thrombocytopenia
title_short Progress in pathophysiological understanding and treatment of thrombocytopenia
title_sort progress in pathophysiological understanding and treatment of thrombocytopenia
topic Progress in Hematology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851102/
https://www.ncbi.nlm.nih.gov/pubmed/36656456
http://dx.doi.org/10.1007/s12185-023-03542-w
work_keys_str_mv AT kashiwagihirokazu progressinpathophysiologicalunderstandingandtreatmentofthrombocytopenia

Ejemplares similares